Human Safety Study of Ebola Vaccine Candidate

Human Safety Study of Ebola Vaccine Candidate

Ebola the uncontrolled outbreak in West Africa which began March 2014 is unprecedented people still dying from the non-preventable disease _ so far_ as no treatment and no vaccine but NIAID the National Institute of Allergy and Infectious Disease will start its step towards the dream of producing the Ebola Vaccine “precious dream” is coming soonthat is Great step in protecting human the NIH starting Human Safety Study of Ebola Vaccine Candidate

Human Safety Study of Ebola Vaccine Candidate

Human Safety Study of Ebola Vaccine Candidate

The NIAID of the National Institute of Health (NIH) accelerating the testing process of the Ebola vaccine that they developed several years by a cooperation between the NIAID and GlaxoSmithKline and testing will conducted soon at the clinical center of NIH at Bethesda The early-stage trial will evaluate the vaccine’s safety and immunogenicity and is the first of several phase 1 clinical trials of Ebola vaccine

The bivalent vaccine uses a chimpanzee adenovirus (chimp adenovirus type 3) as a vector to administer segments of genetic material obtained from the Zaire Ebola and Sudan Ebola species.

A phase 1 clinical trial (VRC 207) will be conducted among 2 groups of ten healthy adults aged between 18 and 20 years, based on expedited FDA approval. The group one will be injected intramuscularly by the experimental vaccine, and the group two will be injected of a higher dose of the same vaccine. Three participants will receive the vaccine and undergo three days of follow-up to establish safety first before the other participants will receive the vaccine. Plus patient data will be reviewed daily plus weekly, also clinical staff will evaluate participants regularly nine times during a 48-week period.

Also, NIH is working with a British-based international consortium including the Wellcome Trust and Department for International Development plus the Medical Research Council to test the vaccine candidate among healthy adult volunteers both in the United Kingdom and Gambia and Mali.

The CDC has begun discussions with Nigerian Ministry of Health officials about conducting a phase one safety study of the vaccine in between healthy adults there.

The VRC 207 trial will also test a monovalent version of the same vaccine that contains genetic material from the Zaire Ebola species only. Also, trial will study that vaccine in twenty healthy adults and is expected to begin this October.

Also, NIH is also working with the international consortium to test the monovalent vaccine candidate among sixty healthy volunteers in the UK and forty healthy volunteers in Mali and among 40 healthy volunteers in Gambia. A trial in the United Kingdom is expected to start mid-September after ethical and regulatory approval.

 

 Join our mailing list to receive our weekly updates